Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583618 · ClinicalTrials.gov registry record · Phase 2
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT04583618 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 750 participants.
The verdict
NCT04583618, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
Primary Objectives: * Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination * Assessed the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
Interventions
- BIOLOGICAL Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
- BIOLOGICAL Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
- BIOLOGICAL Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII
- BIOLOGICAL Pneumococcal 13 - valent conjugate vaccine-Prevnar 13
- BIOLOGICAL Pneumococcal Vaccine Polyvalent-Pneumovax 23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2022-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583618
The ClinicalTrials.gov registry entry for NCT04583618 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb is the first listed.
NCT04583618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583618 about?
NCT04583618 is a clinical study titled "Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.". Primary Objectives: * Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination * Assessed the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
What is the current status of trial NCT04583618?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2020-10-08. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT04583618?
The interventions under investigation include: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb (BIOLOGICAL), Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI (BIOLOGICAL), Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII (BIOLOGICAL), Pneumococcal 13 - valent conjugate vaccine-Prevnar 13 (BIOLOGICAL), Pneumococcal Vaccine Polyvalent-Pneumovax 23 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04583618?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.